Devita, Hellman, and Rosenberg's Cancer

LWBK1006-12 LWW-Govindan-Review November 24, 2011 11:21

136 DeVita, Hellman, and Rosenberg’s CANCER: Principles and Practice of Oncology Review

Question 12.5. What is the mechanism of action for bupropion?

A. Increase synaptic concentration of norepinephrine

B.  2 4 partial agonist and antagonist

C. Blockade of the dopamine reuptake

D. None of the above

Question 12.6. Which of the following neoplasias is NOT an intraepithelial marker for

invasive cancer?

A. Colorectal adenoma

B. Junctional nevus

C. Actinic keratosis

D. Bronchial dysplasia

Question 12.7. In clinical trials, systemic retinoids and beta-carotene were shown to

reduce cancer incidence in this group of high-risk individuals:

A. Skin cancer in patients with xeroderma pigmentosum

B. Lung cancer in heavy smokers

C. Cervical cancer in patients with cervical dysplasia

D. Colorectal cancer in patients with adenoma

Question 12.8. Which of the statements is/are TRUE regarding nonsteroidal anti-

inflammatory drugs (NSAIDs) in the prevention of colorectal cancer?

A. Chemopreventive effects of low-dose aspirin on colorectal cancer

development were demonstrated in clinical trials, and its overall ben-

efits outweigh the risks in adults at average risks of developing col-

orectal cancer.

B. High-dose sulindac prevents the development of new polyps, al-

though it does not cause the regression of established polyps.

C. In randomized trials, both rofecoxib and celecoxib were shown to

reduce the risk of metachronous colorectal adenomas and colorectal

cancer.

D. Considering the risks associated with these agents, screening strategy

alone seems to be sufficient in average-risk adults.

Question 12.9. The risk of which of the following toxicities is increased in patients treated

with raloxifene?

A. Endometrial cancer

B. Vertebral fracture

C. Venous thromboembolism

D. Coronary artery heart disease